These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. How They Did It: Increasing Transparency for Randomized Trial Methods. Brubaker L Female Pelvic Med Reconstr Surg; 2016; 22(4):181. PubMed ID: 27337409 [No Abstract] [Full Text] [Related]
6. Toward sound objective evaluation of clinical measures. Kraemer HC Am J Geriatr Psychiatry; 2013 Jul; 21(7):589-95. PubMed ID: 23764524 [TBL] [Abstract][Full Text] [Related]
7. The revised CONSORT statement: honing the cutting edge of the randomized controlled trial. Shapiro S CMAJ; 2001 Apr; 164(8):1157-8. PubMed ID: 11338802 [No Abstract] [Full Text] [Related]
8. Fundamentals of randomized clinical trials in wound care: reporting standards. Brölmann FE; Eskes AM; Sumpio BE; Mayer DO; Moore Z; Agren MS; Hermans M; Cutting K; Legemate DA; Vermeulen H; Ubbink DT Wound Repair Regen; 2013; 21(5):641-7. PubMed ID: 23937172 [TBL] [Abstract][Full Text] [Related]
9. CONSORT in China: past development and future direction. Song TJ; Leng HF; Zhong LL; Wu TX; Bian ZX Trials; 2015 Jun; 16():243. PubMed ID: 26026311 [TBL] [Abstract][Full Text] [Related]
10. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. Welch VA; Norheim OF; Jull J; Cookson R; Sommerfelt H; Tugwell P; BMJ; 2017 Nov; 359():j5085. PubMed ID: 29170161 [No Abstract] [Full Text] [Related]
12. Ginkgo biloba prevention trials: more than an ounce of prevention learned. Kaye J Arch Neurol; 2009 May; 66(5):652-4. PubMed ID: 19433666 [No Abstract] [Full Text] [Related]
13. Improving the quality of reports of randomised controlled trials: the CONSORT statement. Otwombe KN; Ogutu B East Afr Med J; 2002 Jul; 79(7):394-6. PubMed ID: 12638837 [No Abstract] [Full Text] [Related]
14. The line of 'no difference' is not engraved in stone: the utility of non-inferiority clinical trials. Joshi M; Ananth CV BJOG; 2014 Jul; 121(8):920-2. PubMed ID: 24958567 [No Abstract] [Full Text] [Related]
16. [GRADE guidelines: 12. Developing Summary of Findings tables - dichotomous outcomes]. Langer G; Meerpohl JJ; Perleth M; Gartlehner G; Schünemann H Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):646-64. PubMed ID: 24315336 [TBL] [Abstract][Full Text] [Related]
17. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367 [TBL] [Abstract][Full Text] [Related]
18. The delayed-start study in Parkinson disease: can't satisfy everyone. Olanow CW; Rascol O Neurology; 2010 Apr; 74(14):1149-50. PubMed ID: 20368635 [No Abstract] [Full Text] [Related]
19. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195 [TBL] [Abstract][Full Text] [Related]
20. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Le Cleach L; Chassany O; Levy A; Wolkenstein P; Chosidow O Dermatology; 2008; 216(1):46-55. PubMed ID: 18032899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]